Major advances in the treatment of metastatic non–small cell lung cancer have led to significant incremental improvements in patient outcomes. Platinum-based combination therapy remains the cornerstone of first-line therapy. The…
The landscape for the second- and third-line treatment of advanced non–small cell lung cancer has changed dramatically over the last two decades. Immunotherapeutic agents have become a preferred choice following…
Locally advanced non–small cell lung cancer is a heterogeneous disease with typically poor outcomes. Select patients may benefit from the integration of surgery, whereas patients with bulky, multistation, or contralateral…
The use of 4 cycles of cisplatin-based adjuvant chemotherapy is now the standard of care for patients with resected stage II and IIIA non–small cell lung cancer. Neoadjuvant chemotherapy lacks…
The molecular characterization of lung cancer has changed the classification and treatment of these tumors, becoming an essential component of pathologic diagnosis and oncologic therapy decisions. Through the recognition of…
Targeted therapies and immune checkpoint inhibitors have significantly improved outcomes in a sizable fraction of patients with metastatic non-small cell lung cancer. Nevertheless, a majority of patients with lung cancer…
Daniel Morgensztern, MD, Editor Roy S. Herbst, MD, PhD, Editor Lung cancer is the leading cause of cancer mortality worldwide. Despite the poor outcomes, particularly for patients with advanced stage,…
